Also in last week's Mailbag, I mentioned Clovis Oncology (CLVS) as a company I liked after seeing the company present at a recent investor conference. This prompted an email from a buyside investor who's not a fan of Clovis' pancreatic cancer drug CO-101. I'm not allowed to use his name but his comments accurately describe the Clovis bear thesis:
"If you read the published papers, particularly the in vitro and animal data, you can see that this is a sure failure. The Clovis drug [CO-101] becomes free gemcitabine about 15 minutes after it enters the body. They also left off that under normal circumstances it takes 10 times the dose and 2 times the time for the Clovis drug to produce the same active form of gemcitabine inside the cell as it does with normal gemcitabine. Finally, the Clovis drug did slightly worse than gemcitabine in animals with tumors that have the blocked channel Clovis supposedly overcomes," this Clovis bear writes.
Clovis is expected to announce top-line results from a phase III study of CO-101 in pancreatic cancer before the end of the year.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV